A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Study Acronym: EndoMAP
Study Information
Alliance Study ID: AFT-50
NCT Study ID (ClinicalTrials.gov): NCT04486352
Alliance Committee: Genitourinary Cancer
Disease or Cancer Type: Gynecologic Cancers – Ovarian / Uterine / Cervical / Endometrial
Alliance Study Chair: Brian Slomovitz, MD
Status: RECRUITING
Study Description
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Locations (21)
City of Hope Comprehensive Cancer Center
Duarte, California 91010
United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California 94143
United States
Medstar Georgetown Cancer Institute
Washington D.C., District of Columbia 20007
United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida 33140
United States
University of Chicago
Chicago, Illinois 60637
United States
University of Kansas Cancer Center
Westwood, Kansas 66205
United States
Maine Medical Center
Scarborough, Maine 04074
United States
Dana Farber Cancer Institute
Boston, Massachusetts 02125
United States
University of Minnesota
Minneapolis, Minnesota 55455
United States
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri 63110
United States
Nebraska Methodist Hospital
Omaha, Nebraska 68114
United States
Englewood Health
Englewood, New Jersey 07631
United States
Atlantic Health Systems/Morristown Medical Center
Morristown, New Jersey 07960
United States
Roswell Park
Buffalo, New York 14263
United States
Weill Cornell Medicine
New York, New York 10065
United States
Duke University Cancer Center
Durham, North Carolina 27710
United States
University of Oklahoma Health Stephenson Cancer Center
Oklahoma City, Oklahoma 73104
United States
Providence Portland Cancer Institute
Portland, Oregon 97213
United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania 15261
United States
Lifespan – Rhode Island Hospital
Providence, Rhode Island 02903
United States
Baptist Memorial Hospital
Memphis, Tennessee 38120
United States
Data Sources & Contacts
Full trial details
For more Information